scholarly journals Food phytochemicals against Helicobacter pylori

2021 ◽  
Vol 14 (1) ◽  
pp. 11-17
Author(s):  
Alexandru Mandici ◽  
◽  
Alina-Alexandra Covrig ◽  
Irina Macovei ◽  
◽  
...  

H. pylori is a widespread pathogen, being the main culprit behind gastric and peptic ulcers with possible implications in the development of gastric cancers. In vitro studies have shown that ellagic acid and derivatives present in significant amounts in fruits and leaves have moderate bactericidal effects on H. pylori, while resveratrol was noted to inhibit urease enzyme as high as 90% in different strains of H. pylori. Quercetin seems to inhibit pathogen’s VacA enzyme and kaempferol may prevent translocation of CagA, both phytochemicals being found in significant amounts in berries. In one clinical study, allicin was found to act synergically with standard antibiotic regimens. Although in vitro results seem promising, in vivo studies did not underline significant clinical benefits of phytochemicals compared to standard therapy. Therefore, further studies are needed to accurately estimate any clinical benefit of dietary phytochemicals in H. pylori infection.

2019 ◽  
Vol 63 (6) ◽  
Author(s):  
Yanqiang Huang ◽  
Xudong Hang ◽  
Xueqing Jiang ◽  
Liping Zeng ◽  
Jia Jia ◽  
...  

ABSTRACTHelicobacter pyloriis a major global pathogen, and its infection represents a key factor in the etiology of various gastric diseases, including gastritis, peptic ulcers, and gastric carcinoma. The efficacy of current standard treatment forH. pyloriinfection including two broad-spectrum antibiotics is compromised by toxicity toward the gut microbiota and the development of drug resistance, which will likely only be resolved through novel and selective antibacterial strategies. Here, we synthesized a small molecule, zinc linolenate (ZnLla), and investigated its therapeutic potential for the treatment ofH. pyloriinfection. ZnLla showed effective antibacterial activity against standard strains and drug-resistant clinical isolates ofH. pyloriin vitrowith no development of resistance during continuous serial passaging. The mechanisms of ZnLla action againstH. pyloriinvolved the disruption of bacterial cell membranes and generation of reactive oxygen species. In mouse models of multidrug-resistantH. pyloriinfection, ZnLla showedin vivokilling efficacy comparable and superior to the triple therapy approach when use as a monotherapy and a combined therapy with omeprazole, respectively. Moreover, ZnLla treatment induces negligible toxicity against normal tissues and causes minimal effects on both the diversity and composition of the murine gut microbiota. Thus, the high degree of selectivity of ZnLla forH. pyloriprovides an attractive candidate for novel targeted anti-H. pyloritreatment.


2000 ◽  
Vol 118 (4) ◽  
pp. A730 ◽  
Author(s):  
Edhi S. Gunawan ◽  
Shingo Tsuji ◽  
Masahiko Tsujii ◽  
Wei-Hao Sun ◽  
Yutaka Sazaki ◽  
...  
Keyword(s):  

2003 ◽  
Vol 47 (10) ◽  
pp. 3240-3246 ◽  
Author(s):  
G. E. Bergonzelli ◽  
D. Donnicola ◽  
N. Porta ◽  
I. E. Corthésy-Theulaz

ABSTRACT An increased density of Helicobacter pylori in the gastric mucosa can be associated with more severe gastritis and an increased incidence of peptic ulcers. Therefore, people with asymptomatic gastritis would certainly benefit from a nutritional approach to help them manage the infection and therefore decrease the risk of development of associated pathologies. We analyzed the activities of 60 essential oils against H. pylori P1 and identified 30 oils that affected growth, with in vitro inhibition zones ranging between 0.7 and 6.3 cm in diameter. We further analyzed the effects of 16 oils with different activities on H. pylori P1 viability. Fifteen showed strong bactericidal activities, with minimal bactericidal concentrations after 24 h ranging from 0.02 to 0.1 g/liter at pH 7.4. Even though slight variations in activities were observed, the essential oils that displayed the strongest bactericidal potentials against H. pylori P1 were also active against other Helicobacter strains tested. Among the pure constituents of different essential oils tested, carvacrol, isoeugenol, nerol, citral, and sabinene exhibited the strongest anti-H. pylori activities. Although oral treatment of H. pylori SS1-infected mice with carrot seed oil did not result in significant decreases in the bacterial loads in the treated animals compared to those in the control animals, in all experiments performed, the infection was cleared in 20 to 30% of carrot seed oil-treated animals. Our results indicate that essential oils are unlikely to be efficient anti-Helicobacter agents in vivo. However, their effects may not be irrelevant if one plans to use them as food additives to complement present therapies.


2021 ◽  
Vol 23 (Supplement_1) ◽  
pp. i45-i45
Author(s):  
Ian Mersich ◽  
Biplab Dasgupta

Abstract Diffuse intrinsic pontine glioma is a universally lethal disease primarily impacting pediatric patients. There are currently no targeted therapies increasing overall for patients with these tumors; therefore, our lab set out to elucidate metabolic dependencies in DIPG patient-derived cell lines with the ultimate goal of identifying novel therapeutic targets. Through untargeted metabolomics and gene expression analyses, we have identified the purine metabolism gene ATIC to be important for DIPG tumor cell survival and proliferation. Anti-folate drugs such as methotrexate target de novo purine biosynthesis and are used to treat other pediatric cancers; however, we have identified a small molecule inhibitor of ATIC that may offer clinical benefits over other inhibitors of this pathway. In vitro cell viability experiments have demonstrated DIPG cell lines are much more sensitive to the ATIC inhibitor relative to normal neural stem cells and glial cell lines. Furthermore, we have started in vivo studies on pre-clinical mouse models of DIPG with promising results. Treatment with the ATIC inhibitor has significantly increased overall survival relative to control and vehicle treated mice. The dosage we started at was well tolerated in these mice so we are following up on this in vivo work through dose-escalation studies as well as combination treatment strategies. Mechanistically, the ATIC inhibitor works differently than anti-folate compounds such as methotrexate; therefore we are also elucidating why cancer cells are much more sensitive to this compound.


1996 ◽  
Vol 17 (3) ◽  
pp. 178-180
Author(s):  
Edward K. Chapnick ◽  
Jeremy D. Gradon ◽  
Barry Kreiswirth ◽  
Larry I. Lutwick ◽  
Benjamin C. Schaffer ◽  
...  

AbstractThe in vitro activities of bacitracin and mupirocin were compared for seven different strains of methicillin-resistant Staphylococcus aureus. Six of seven strains showed bacitracin minimum inhibitory concentrations (MICs) of 0.5 to 1.0 units/mL, and all seven had mupirocin MICs of 0.5 to 2 μg/mL. Time-kill studies revealed 2.6- to 4.5-log reduction in 24 hours with strains susceptible to bacitracin (4 units/mL) and 0 to 2.2 reduction with mupirocin (16 μg/mL). Bacitracin should be considered further for in vivo studies because of enhanced bacteriocidal effect and lower cost.


2021 ◽  
Vol 9 (4) ◽  
pp. 860
Author(s):  
Gizem Levent ◽  
Robin C. Anderson ◽  
Branko Petrujkić ◽  
Toni L. Poole ◽  
Haiqi He ◽  
...  

The gut of food-producing animals is a reservoir for foodborne pathogens. Thymol is bactericidal against foodborne pathogens but rapid absorption of thymol from the proximal gut precludes the delivery of effective concentrations to the lower gut where pathogens mainly colonize. Thymol-β-d-glucopyranoside is reported to be more resistant to absorption than thymol in everted jejunal segments and could potentially function as a prebiotic by resisting degradation and absorption in the proximal gut but being hydrolysable by microbial β-glycosidase in the distal gut. Previous in vitro studies showed bactericidal effects of thymol-β-d-glucopyranoside against Campylobacter, Escherichia coli, and Salmonella enterica serovar Typhimurium in the presence but not absence of intestinal microbes expressing β-glycosidase activity, indicating that hydrolysis was required to obtain antimicrobial activity. Presently, the oral administration of thymol-β-d-glucopyranoside was studied to examine the effects on intestinal carriage of Campylobacter, E. coli, and S. Typhimurium in swine. The effects of thymol-β-d-glucopyranoside or thymol on antimicrobial sensitivity of representative E. coli isolates and characterized Salmonella strains were also explored. Results from two in vivo studies revealed little antimicrobial effects of thymol-β-d-glucopyranoside on Campylobacter, E. coli, or S. Typhimurium in swine gut. These findings add credence to current thinking that hydrolysis and absorption of thymol-β-d-glucopyranoside and thymol may be sufficiently rapid within the proximal gut to preclude delivery to the distal gut. Antibiotic susceptibilities of selected bacterial isolates and strains were mainly unaffected by thymol. Further research is warranted to overcome obstacles, preventing the delivery of efficacious amounts of thymol-β-d-glucopyranoside to the lower gut.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 958-958
Author(s):  
Emma Castro ◽  
Nuria Gironés ◽  
José Luis Bueno ◽  
Javier Carrión ◽  
Manuel Fresno

Abstract Introduction.Transfusion-associated Chagas’ disease has been transmitted by labile blood components in endemic countries. In addition, at least 6 cases have occurred in the USA and Canada, due to platelets. In many countries, no test to prevent transfusion-transmission of T. cruzi is in routine use. This study evaluated the efficacy of photochemical treatment (PCT) to inactivate T. cruzi in contaminated platelet components. Methods. Paired platelet components were prepared as follows. 3 pooled ABO matched buffy-coat platelet components (BC-PLT) were combined, and then re-divided into 3 BC-PLT units of approximately 300 mL. Each BC-PLT unit was inoculated with a high dose (5x103/mL) of viable T. cruzi metacyclic trypomastigotes obtained from mice infected with either the G, Tulahuen (T) or Y strains. Five pools of 3 BC-PLT units each were assayed for infectivity before and after PCT with the INTERCEPT system (150 μM amotosalen + 3 J/cm2). Infectivity was determined with 3 different methods by assaying 10 mL samples for parasite viability as follows: 1) in vitro culture to detect viable epimastigotes; 2) 3H-Thymidine incorporation in culture; and 3) in vivo inoculation into Interferon-γ Receptor (IFN-γR) deficient mice, highly susceptible to T. cruzi infection. For all BC-PLT units, 10 mL aliquots of each platelet unit were taken before inoculation as negative controls (NC), after parasite inoculation before PCT as positive controls (PC), and after PCT. In vitro cultures were seeded, observed weekly and parasitemia calculated at 30 days post-inoculation(d.p.i) as parasites/mL (p/mL) by limiting dilution analysis. At 30 d.p.i, cultures were pulsed with 3H-Thymidine for 16 hours, cultures were harvested and counts per minute (c.p.m.) measured. In the in vivo study, mice were inoculated intraperitoneally with BC-PLT (10 mL concentrated to 1 mL) and parasitemia was monitored at 7, 14, 21 and 28 d.p.i. Survival of mice was followed up for more than 2 months post inoculation. Results. After 30 days follow up, no viable parasites were detected in PCT BC-PLT by any of the 3 viability assays, and with any of the 3 T. cruzi strains tested. Only the untreated PC samples showed the presence of the replicative form of the parasite by in vitro cultures derived from the 3 different T. cruzi strains. PC from BC-PLT contaminated with the different strains contained 7812, 550, and 100 parasites/mL for the Y, T and G strains, respectively, by in vitro cultures. PC, but not PCT BC-PLT samples, showed significant incorporation of 3H-Thymidine. In addition, in vivo studies showed that only mice inoculated with PC died as a result of the infection. Moreover, 100% of mice died at 14, 28 and 38 days after inoculation with PC containing the Y, T and G strains, respectively. All mice inoculated with NC and PCT BC-PLT aliquots were alive after more than 2 months post-exposure. Conclusions.The pathogen reduction system using Amotosalen HCl and UVA demonstrated robust efficacy for inactivation of high doses of 3 different strains of T. cruzi . This PCT system offers the potential to make the platelet supply safer in countries with T. cruzi endemicity and in countries with growing immigrant blood donor populations from Latin America and other regions in which T. cruzi is endemic.


2019 ◽  
Vol 27 (1) ◽  
pp. 63-71 ◽  
Author(s):  
Muhammet Murat Celik ◽  
Nizami Duran

Abstract Aim: The aim of this study was to investigate the in-vitro efficacy of Glycyrrhetinic acid against Helicobacter pylori (H. pylori) strains, as compared with conventional antibacterial agents. Methods: A total of 41 H. pylori isolates were used, 6 of which were of standard strains (NCTC 1637), 8 of which were drug-sensitive, and 27 were resistant to drugs isolates. Clarithromycin and metronidazole resistance in all strains of H. pylori were determined by the Epsilometer test (E-test) method. MIC study was performed by using microdilution broth method. Results: Glycyrrhetinic acid was found to be effective against H. pylori NCTC 1637 in doses of 12.0±4.38 µg/mL, while the MIC value of clinical H. pylori isolates susceptible to antimicrobials was 20.8±10.11 µg/ml. It was found that the MIC values for antimicrobial-sensitive clinical H. pylori isolates was higher when compared with H. pylori NCTC 1637 strains. The MIC values of the standard antimicrobial agents against drug-resistant H. pylori strains were higher than H. pylori NCTC 1637 strains and drug-sensitive H. pylori strains. The MIC value was found to be 14.22±7.77 µg/ml for metronidazole, 3.89±1.90 µg/ml for clarithromycin, 2.33±1.0 µg/ml for amoxicillin, 2.44±0.88 µg/ml for levofloxacin and 4.89±2.47 µg/ml for tetracycline, whereas the MIC value of Glycyrrhetinic acid was 26.67±8.0 µg/ml in metronidazole-resistant H. pylori isolates. Besides, MIC values of the antimicrobials and 18ß-Glycyrrhetinic acid among the strains resistant to clarithromycin were as follows: 3.25±2.12 µg/ml for metronidazole, 9.71±4.54 µg/ml for clarithromycin, 2.06±1.32 µg/ml for amoxicillin, 3.88±4.22 µg/ml for levofloaxacin and 3.25±1.04 µg/mL for tetracycline and 22.0±11.11 µg/ml for Glycyrrhetinic acid. Conclusion: Glycyrrhetinic acid had significant antimicrobial activity against H. pylori strains. Although further in-vivo studies are needed on antimicrobial activity of Glycyrrhetinic acid, increased resistance to drugs currently used in treatment suggests that Glycyrrhetinic acid may be a potential agent for the treatment of H. pylori.


Biomolecules ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 265 ◽  
Author(s):  
Larissa Lucena Périco ◽  
Maycon Tavares Emílio-Silva ◽  
Rie Ohara ◽  
Vinícius Peixoto Rodrigues ◽  
Gabriela Bueno ◽  
...  

Peptic ulcer disease (PUD) is a multifactorial and complex disease caused by an imbalance of protective and aggressive factors (endogenous and exogenous). Despite advances in recent years, it is still responsible for substantial mortality and triggering clinical problems. Over the last decades, the understanding of PUD has changed a lot with the discovery of Helicobacter pylori infection. However, this disease continues to be a challenge due to side-effects, incidence of relapse from use of various anti-ulcer medicines, and the rapid appearance of antimicrobial resistance with current H. pylori therapies. Consequently, there is the need to identify more effective and safe anti-ulcer agents. The search for new therapies with natural products is a viable alternative and has been encouraged. The literature reports the importance of monoterpenes based on the extensive pharmacological action of this class, including wound healing and anti-ulcerogenic agents. In the present study, 20 monoterpenes with anti-ulcerogenic properties were evaluated by assessing recent in vitro and in vivo studies. Here, we review the anti-ulcer effects of monoterpenes against ulcerogenic factors such as ethanol, nonsteroidal anti-inflammatory drugs (NSAIDs), and Helicobacter pylori, highlighting challenges in the field.


2019 ◽  
Vol 8 (1) ◽  
pp. 90 ◽  
Author(s):  
Yi-Hsing Chen ◽  
Wan-Hua Tsai ◽  
Hui-Yu Wu ◽  
Chun-Ya Chen ◽  
Wen-Ling Yeh ◽  
...  

The bacterial species, Helicobacter pylori, is associated with several gastrointestinal diseases, and poses serious health threats owing to its resistance to antibiotics. Lactobacillus spp., on the other hand, possess probiotic activities that have beneficial effects in humans. However, the mechanisms by which Lactobacillus spp. harbor favorable functions and act against H. pylori infection remain to be explored. The aim of this study was to investigate the ability of bacterial strains, Lactobacillus rhamnosus and Lactobacillus acidophilus, termed GMNL-74 and GMNL-185, respectively, to inhibit H. pylori growth and inflammation. Our results showed that GMNL-74 and GMNL-185 possess potent antimicrobial activity against multidrug resistant (MDR)-H. pylori. In addition, an in vitro cell-based model revealed that the inhibition of H. pylori adhesion and invasion of gastric epithelial cells and interleukin-8 production were significantly decreased by treatment with both the Lactobacillus strains. In vivo studies demonstrated that colonization of H. pylori and induced inflammation in the mouse stomach were also alleviated by these Lactobacillus strains. Furthermore, the abundance of beneficial gut bacteria, including Bifidobacterium spp. and Akkermansia muciniphilia, were significantly increased in H. pylori-infected mice treated with GMNL-74 and GMNL-185. These results demonstrate that Lactobacillus spp. ameliorate H. pylori-induced inflammation and supports beneficial gut specific bacteria that act against H. pylori infection.


Sign in / Sign up

Export Citation Format

Share Document